ACCO + CpG

**ACCO + CpG** is an investigational combination of two agents for cancer immunotherapy: **ACCO**, an unspecified agent (likely a proprietary or code-name drug, as no details are provided in the search results), and **CpG**, short for *CpG oligodeoxynucleotide*, which are short synthetic DNA sequences containing unmethylated CpG motifs that function as potent immunostimulants by targeting Toll-like receptor 9 (TLR9) on immune cells[7]. CpG oligodeoxynucleotides activate innate and adaptive immune responses, enhance antigen presentation, and stimulate anti-tumor activity. In cancer therapy, CpG ODN has been trialed to boost the efficacy of other treatments such as monoclonal antibodies, chemotherapy, and cancer vaccines[7]. Combinations of CpG ODN with other agents, including investigational drugs, are being studied primarily in the context of **oncology**, in particular for solid and hematologic malignancies.